You are here

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
Glendale, California, 91206 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease, Healthy Subjects
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old
(subjects with Alzheimer's Disease)

- Women must be surgically sterile or postmenopausal

- Subjects with Alzheimer's Disease must be generally healthy, but may have a stable,
chronic illness if well controlled.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Healthy subjects may not be on any prescription or investigation drugs within 30 days
of start of study.

- Subjects with Alzheimer's Disease may not be on any cholinesterase inhibitors such as
donepezil (Aricept®) or rivastigmine (Exelon®) within 4 weeks of the start of the
study.

NCT00795730
Pfizer
Terminated
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now